Development asset linked to Lisata Therapeutics in public FDA and regional records.
pharma · Covid-19 · Chronic Myocardial Ischemia · LSTA
Lisata Therapeutics
LISATA THERAPEUTICS, INC.
Lisata Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US HQ
2006 Founded
38 Employees
Public company Type
LSTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US
- Founded
- 2006
- Employees
- 38
- Programs
- 15
- Drugs
- 13
- Patents
- 1
Lisata Therapeutics pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lisata Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Lisata Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.
-
Development asset linked to Lisata Therapeutics in public FDA and regional records.